-25. Jan. 20192 Min. LesezeitOrigenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics . . .January 25, 2019 Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies...
-22. März 20181 Min. LesezeitOrigenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business OfficerMarch 22, 2018 Origenis GmbH, a Germanbiotech company specializing in the discovery and development of highly selective small...
-23. Mai 20171 Min. LesezeitOrigenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment . . . May 23, 2017 Worldwide DistributionOrigenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of...